Drugs / Anti-BCMA-GPRC5D CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06515262 | Jul 2024 → Nov 2026 expected | refractory plasma cell neoplasm | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-BCMA-GPRC5D CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515262 ↗ |
| Modality | Cell therapy | “Anti-BCMA-GPRC5D chimeric antigen receptor (CAR) modified T cells” NCT06515262 ↗ |
| Route | Intravenous | “receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells” NCT06515262 ↗ |
| Target | GPRC5D | “bispecific BCMA-GPRC5D CAR-T cells” NCT06515262 ↗ |